A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

December 4, 2020

Study Completion Date

December 4, 2020

Conditions
XLH
Interventions
DRUG

KRN23

The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.

Trial Locations (10)

Unknown

Hokkaido University Hospital, Sapporo

Kanagawa Prefectural Hospital Organization Kanagawa Children's Medical Center, Yokohama

National University Corporation Osaka University, Suita

The University of Tokyo Hospital, Bunkyō-Ku

Toranomon Hospital, Minato-Ku

Okayama Saiseikai General Hospital, Okayama

Japan Community Health Care Organization Osaka Hospital, Osaka

Osaka City University Hospital, Osaka

Asan Medical Center, Seoul

Seoul National University hospital, Seoul

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04308096 - A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia | Biotech Hunter | Biotech Hunter